About the Company
MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MYOK News
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, ...
BMS bulks up in cardio with $13.1bn takeover deal for MyoKardia
Bristol-Myers Squibb has said it will buy biotech MyoKardia in a $13.1 billion takeover that marks a step up in its development of cardiovascular drugs. The all-cash deal is mainly about MyoKardia ...
Bristol-Myers Shares Gain After Positive Data From Opdivo Lung Cancer Trial
Earlier this week, Britsol-Myers agreed to buy drugmaker MyoKardia Inc. (MYOK) , which makes the experimental heart treatment mavacamten, for around $13.1 billion and reiterated its existing ...
FULC Fulcrum Therapeutics, Inc.
and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge ...
Stock Market Today With Jim Cramer: Stimulus For Airlines
Its much larger than $13 billion." On Monday, Britsol-Myers Squibb Co. agreed to buy drugmaker MyoKardia Inc. which makes the experimental heart treatment Mavacamten, for around $13.1 billion.
Avidity (RNA) Expands Collaboration With BMY, Shares Rise
Shares of Avidity Biosciences, Inc. RNA surged 14.9% following the ... Avidity announced a research collaboration with MyoKardia in 2021 to demonstrate the potential utility of antibody oligonucle ...
Diabetes drug improves cardiovascular outcomes across a range of heart and kidney conditions
Patel, Kang, Im, Sabatine and Wiviott are members of the TIMI Study Group, which has received institutional grant support through Brigham and Women’s Hospital from Abbott, Abiomed, Inc., Amgen ...
MPW Medical Properties Trust, Inc.
Medical Properties Trust, Inc. is a self-advised real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities. From its inception in Birmingham, Alabama ...
About Inc.com | Everything You Need to Know to Grow and Start Your Business
Inc. is the voice of the American entrepreneur. We inspire, inform, and document the most fascinating people in business: the risk-takers, the innovators, and the ultra-driven go-getters that ...
Snap Inc.
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
Apple Inc.
1 Day AAPL -1.22% DJIA 0.56% S&P 500 -0.88% Technology -5.78% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum ...
Fulcrum Therapeutics Inc (FULC)
Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week: upgrades for Netflix, Fulcrum Therapeutics, and Grab Holdings, and downgrades for Medical... Fulcrum ...
Loading the latest forecasts...